Nektar Therapeutics Inc., of San Francisco, said its oncology candidate, NKTR-102, received orphan drug status for ovarian cancer from the FDA. It is involved in an ongoing Phase II study enrolling approximately 125 patients with platinum-resistant ovarian cancer with progression following pegylated liposomal doxorubicin.